Compare CTBI & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTBI | EYPT |
|---|---|---|
| Founded | 1903 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 1995 | 2005 |
| Metric | CTBI | EYPT |
|---|---|---|
| Price | $65.53 | $13.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $63.00 | $31.80 |
| AVG Volume (30 Days) | 83.8K | ★ 852.2K |
| Earning Date | 04-15-2026 | 05-01-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | ★ 17.79 | N/A |
| EPS | ★ 5.43 | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | $14.02 | N/A |
| Revenue Next Year | $4.30 | $3,115.57 |
| P/E Ratio | $12.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $48.48 | $5.46 |
| 52 Week High | $68.50 | $19.11 |
| Indicator | CTBI | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 59.71 | 45.98 |
| Support Level | $55.30 | $13.61 |
| Resistance Level | $65.64 | $14.54 |
| Average True Range (ATR) | 1.47 | 0.62 |
| MACD | 0.08 | 0.07 |
| Stochastic Oscillator | 58.23 | 43.66 |
Community Trust Bancorp Inc is a bank holding company. The Bank owns all the capital stock of one commercial bank and one trust company, serving small and mid-sized communities in eastern, north-eastern, central, and south-central Kentucky, southern West Virginia, and north-eastern Tennessee. Through its subsidiaries, the Bank is engaged in commercial and personal banking and trust and wealth management activities, which include accepting time and demand deposits; making secured and unsecured loans to corporations, individuals, and others; providing cash management services to corporate and individual customers; issuing letters of credit; renting safe deposit boxes; and providing funds transfer services. The company operates in one reportable segment: community banking services.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.